Circulating miRNA-155 as a Potential Biomarker for Coronary Slow Flow
Table 1
Basic clinical characteristics of the study participants.
Variable
CSF group ()
Control group ()
value
Male
30 (45.4)
35 (46.7)
0.524
Age (years)
57.18 ± 9.43
55.31 ± 9.82
0.387
BMI (kg/m2)
24.2 ± 2.9
23.7 ± 3.3
0.536
Hypertension
22 (33.3)
26 (39.4)
0.216
Diabetes mellitus
12 (18.2)
14 (21.2)
0.182
Dyslipidemia
25 (37.9)
22 (33.3)
0.207
Family history of CAD
13 (19.7)
12 (18.2)
0.341
Current smoker
15 (22.7)
13 (19.7)
0.123
Systolic BP (mmHg)
131.02 ± 15.76
133.24 ± 17.13
0.432
Diastolic BP (mmHg)
77.61 ± 11.23
78.49 ± 12.47
0.533
Treatment received
Aspirin
44 (66.7)
40 (60.6)
0.217
Clopidogrelsulfate bisulfate
22 (33.3)
24 (36.4)
0.312
Statins
36 (54.5)
32 (48.5)
0.094
ACEIs/ARBs
18 (27.3)
16 (24.2)
0.356
Beta blockers
20 (30.3)
23 (34.8)
0.174
Calcium antagonists
14 (21.2)
17 (25.8)
0.105
Nitrates
45 (68.2)
41 (62.1)
0.192
Variables measured with number of patients (percentages in parentheses or mean ± SD). CSF: coronary slow flow; BMI: body mass index; CAD: coronary artery disease; BP: blood pressure; LVEF: left ventricular ejection fraction; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin-receptor blockers.
